Hyderabad: Aurobindo Pharma remains focussed on developing complex and differentiated products in multiple areas comprising oncology, hormonal products, biosimilars, depot injections and vaccines to drive the next phase of growth, as per its Annual Report for 2021-22. The Hyderabad-based firm also said it is in the process of commissioning the capacities for some of the complex therapeutic areas, adding that it is committed to grow in its key…
